El Paso, TX, August 22, 2013 – (Accesswie) - Premier Biomedical, Inc. (BIEI) (http://www.premierbiomedical.com/), today announced that the company is pursuing an international patent application for its core technology to treat multiple sclerosis (MS). Development of Premier’s therapy, which is functionally similar to its technology for traumatic brain injury, cancer, and Alzheimer’s disease, is anticipated to occur through the company’s existing research channels. Premier has already registered its technology behind multiple provisional patents in the United States and a Europe National Patent in the areas of cancer, blood sepsis, and Alzheimer’s disease. In total, the company holds nine provisional patent applications and six international patent applications.
In response to this development, Dr. Mitchell S. Felder, Chairman of the Scientific Advisory Board said, “Multiple sclerosis is a devastating disease which has destroyed the lives of many tens of thousands of patients. We believe that Premier Biomedical is on the path to make a very major breakthrough in defeating this illness.”
At a lifetime MS treatment cost of an estimated $1.2 million per patient, and with approximately 400,000 diagnosed cases of MS within the United States alone, the impact of multiple sclerosis on the US economy is nearly $20 billion per year currently. On a worldwide basis, there are nearly 2.5 million confirmed cases of multiple sclerosis.
William A. Hartman, President and CEO of Premier Biomedical, remarked, “Our previously announced joint R&D relationships with the University of Texas at El Paso (UTEP) and the U.S. Department of Defense have effectively multiplied our capabilities and allowed us to produce a series of remarkably exciting and groundbreaking medical developments that are poised to advance the existing medical industry. Our most recent announcements, including one where our patent-pending breast cancer drug significantly out-performed chemotherapy in a mouse study and another announcement where we believe that we have discovered a potential cure for traumatic brain injury leading to clinical depression and suicide ideation, attest to the effectiveness of our technical and organizational capabilities. This latter development alone could elicit significant interest and support from the major organizations associated with sports-related head injuries.”
He continued, “Our medical premise on MS and other diseases is sound: To physically remove the pathophysiologic basis of the disease via extra-corporeal means (i.e., outside the body) without potential dangerous side-effects. I invite any person or organization interested in the rapid development of an available cure for multiple sclerosis or any other major disease to reach out to Premier Biomedical to seek opportunities to participate with us in completing the R&D necessary to bring about the conversion from a laboratory cure to an available medical cure.”
More information regarding Premier Biomedical can be found on their corporate website at http://www.premierbiomedicalinc.com/. A YouTube video of the recent joint US Army-Premier Biomedical press conference is viewable at http://youtu.be/pvXUphEbEuM.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in El Paso, Texas, with offices in Pennsylvania. The Company’s common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol “BIEI.” http://www.premierbiomedicalinc.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Premier Biomedical, Inc.
William A. Hartman, CEO
SOURCE Premier Biomedical, Inc.